-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Anebulo Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2020 to Q3 2024.
- Anebulo Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$2.2M, a 11.3% increase year-over-year.
- Anebulo Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$7.92M, a 31.7% increase year-over-year.
- Anebulo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$8.2M, a 30.1% increase from 2023.
- Anebulo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$11.7M, a 71.9% decline from 2022.
- Anebulo Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$6.83M, a 77.4% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)